The Nucleic Acid Testing is also known as NAT (Nucleic Acid Test) or NAAT (Nucleic Acid Amplification Test). The NAT helps in detection of pathogens even when there are no relative clinical signs for the disease. These tests are helpful in the detection of the viral DNAs or RNAs in blood samples of patients. Three major processes involved in NAT are sample pooling and nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection. Nucleic Acid Testing has been widely used for Viral and Bacterial Infectious Diseases, Cancerous diseases, Forensic Testing, Genetically related Diseases and Paternity Testing/HLA Typing. Major NAT technologies include polymerase chain reaction (PCR) used for specificity, strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) nucleic acid sequence based amplification (NASBA) and whole genome sequencing.
Nucleic Acid Testing Market: Drivers and Restraints
The NAT market is the most rapidly growing segment of the in vitro diagnostics industry. Major drivers include prevalence of infectious bacterial and viral diseases, cancer and genetic diseases. About 16% of total deaths each year are due to infectious diseases worldwide. According to 2012 report, it was estimated that around 1 Bn people suffered from infectious diseases which is a major segment of the NAT market. Regulatory mechanisms and reforms are directed towards the burgeoning of the market. In the coming years, NAT market will experience innovation and technological advancement specifically in the automation and reagent systems due to the rising demand and growing end user acceptance for these products. However, the cost containment is a major hindrance for the decrease in penetration rate in the clinical laboratories end user segment, which will be favorable only if cost effective products are introduced in the market. Also a cut down in reimbursement policies in developed nations and insufficient policies in the developing countries will act as a restraining factor for the growth of NAT market.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1106
Nucleic Acid Testing Market: Segmentation
The global Nucleic Acid Testing market is classified on the basis of application, technology, end user, and geography.
Based on application, the global nucleic acid testing market is segmented into the following:
- Infectious diseases
- Bacterial tests
- Viral detection & load
- Viral &bacterial genotyping
- Blood screening
- Cervical cancer screening
- Chromosomal aberrations
- Breast Cancer
- Genetic testing
- Disease predisposition
- Forensic Testing
- Paternity Testing/HLA Typing
Based on technologies, the global nucleic acid testing market is segmented into the following:
- Polymerase chain reaction (PCR)
- Strand displacement amplification (SDA)
- Ligase chain reaction (LCR)
- Transcription-mediated amplification (TMA)
- Nucleic acid sequence based amplification (NASBA)
- Whole genome sequencing
Based on end user, the global nucleic acid testing market is segmented into the following:
- Centralized clinical laboratories
- R&D centers
- Academic institutions
Nucleic Acid Testing Market: Overview
Nucleic Acid Testing was initialized in the year 1999, and thus it is considered as the as thriving market and has tremendous opportunity in the near future. The recent years have seen development of highly advanced innovative technologies which has helped in detection and has shown sensitivity and specificity to the viral infections. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. The NAT market is currently underpenetrated and in its nascent stage of development. Although the maximum revenues are generated by the developed countries, it is also observed that CAGR in the developing countries are high. The reason for the growth in the CAGR can be attributed to the increasing awareness in the latest innovative testing methods and the continuously improving economic conditions. Nucleic Acid testing market is growing with a significant CAGR because of its high adoption rate in treatment of chronic wounds.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1106
Nucleic Acid Testing Market: Region-wise Outlook
On the basis of geography, Global Nucleic Acid Testing Market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. North America contributes maximum share to the Global Nucleic Acid Testing Market. European countries are projected to represent significant growth rates due to the high adoption rate of Nucleic Acid Testing for detection of various pathogenic infections. Asia Pacific is expected to grow at a remarkable CAGR for Nucleic Acid Testing market due to increase in healthcare awareness. Amongst the Asian countries, India and China are more promising due to large population pool and increased prevalence of infectious diseases in these countries.
Nucleic Acid Testing Market: Key Players
Key players in the global Nucleic Acid Testing market include Abbott Laboratories, Inc., Becton, Dickinson and Company, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Siemens Healthcare, Hologic, bioMérieux SA, Novartis AG, F. Hoffmann-La Roche Ltd., Sequenom, Inc. and Tecan Group Ltd.Local Players also have a significant presence in Nucleic Acid Testing Market.
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
Mr. Sudip Saha